Paclitaxel anti-cancer therapeutics: from discovery to clinical use

IF 4 2区医学 Q1 INTEGRATIVE & COMPLEMENTARY MEDICINE

Chinese Journal of Natural Medicines Pub Date : 2025-07-01 DOI:10.1016/S1875-5364(25)60833-8

Haizheng Yu , Fen Lan , Yuan Zhuang , Qizhang Li , Lianqing Zhang , Hongchang Tian , Xiao Bu , Ruibing Chen , Yingying Gao , Zhuo Wang , Lei Zhang

{"title":"Paclitaxel anti-cancer therapeutics: from discovery to clinical use","authors":"Haizheng Yu , Fen Lan , Yuan Zhuang , Qizhang Li , Lianqing Zhang , Hongchang Tian , Xiao Bu , Ruibing Chen , Yingying Gao , Zhuo Wang , Lei Zhang","doi":"10.1016/S1875-5364(25)60833-8","DOIUrl":null,"url":null,"abstract":"<div><div>Paclitaxel (PTX), a valuable natural product derived from <em>Taxus</em> species, exhibits remarkable anti-cancer properties. It penetrates nanopores in microtubule walls, interacting with tubulin on the lumen surface and disrupting microtubule dynamics, thereby inducing cytotoxic effects in cancer cells. PTX and its derivatives have gained approval for treating various diseases due to their low toxicity, high efficiency, and broad-spectrum application. The widespread success and expanding applications of PTX have led to increased demand, raising concerns about accessibility. Consequently, researchers globally have focused on developing alternative production methods and applying nanocarriers in PTX delivery systems to enhance bioavailability. This review examines the challenges and advancements in PTX sourcing, production, physicochemical properties, anti-cancer mechanisms, clinical applications, trials, and chemo-immunotherapy. It aims to provide a comprehensive reference for the rational development and effective utilization of PTX.</div></div>","PeriodicalId":10002,"journal":{"name":"Chinese Journal of Natural Medicines","volume":"23 7","pages":"Pages 769-789"},"PeriodicalIF":4.0000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Chinese Journal of Natural Medicines","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1875536425608338","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INTEGRATIVE & COMPLEMENTARY MEDICINE","Score":null,"Total":0}

引用次数: 0

Abstract

Paclitaxel (PTX), a valuable natural product derived from Taxus species, exhibits remarkable anti-cancer properties. It penetrates nanopores in microtubule walls, interacting with tubulin on the lumen surface and disrupting microtubule dynamics, thereby inducing cytotoxic effects in cancer cells. PTX and its derivatives have gained approval for treating various diseases due to their low toxicity, high efficiency, and broad-spectrum application. The widespread success and expanding applications of PTX have led to increased demand, raising concerns about accessibility. Consequently, researchers globally have focused on developing alternative production methods and applying nanocarriers in PTX delivery systems to enhance bioavailability. This review examines the challenges and advancements in PTX sourcing, production, physicochemical properties, anti-cancer mechanisms, clinical applications, trials, and chemo-immunotherapy. It aims to provide a comprehensive reference for the rational development and effective utilization of PTX.

查看原文本刊更多论文

紫杉醇抗癌药物：从发现到临床应用

紫杉醇（Paclitaxel， PTX）是一种从红豆杉属植物中提取的有价值的天然产物，具有显著的抗癌作用。它穿透微管壁的纳米孔，与管腔表面的微管蛋白相互作用，破坏微管动力学，从而诱导癌细胞的细胞毒性作用。PTX及其衍生物因其低毒、高效、广谱应用而被批准用于治疗多种疾病。PTX的广泛成功和不断扩大的应用导致了需求的增加，引起了人们对可及性的关注。因此，全球研究人员一直致力于开发替代生产方法，并在PTX递送系统中应用纳米载体来提高生物利用度。本文综述了PTX的来源、生产、理化性质、抗癌机制、临床应用、试验和化学免疫治疗等方面的挑战和进展。旨在为PTX的合理开发和有效利用提供综合参考。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Chinese Journal of Natural Medicines INTEGRATIVE & COMPLEMENTARY MEDICINE-PHARMACOLOGY & PHARMACY

CiteScore

7.50

自引率

4.30%

发文量

2235

期刊介绍： The Chinese Journal of Natural Medicines (CJNM), founded and sponsored in May 2003 by China Pharmaceutical University and the Chinese Pharmaceutical Association, is devoted to communication among pharmaceutical and medical scientists interested in the advancement of Traditional Chinese Medicines (TCM). CJNM publishes articles relating to a broad spectrum of bioactive natural products, leading compounds and medicines derived from Traditional Chinese Medicines (TCM). Topics covered by the journal are: Resources of Traditional Chinese Medicines; Interaction and complexity of prescription; Natural Products Chemistry (including structure modification, semi-and total synthesis, bio-transformation); Pharmacology of natural products and prescription (including pharmacokinetics and toxicology); Pharmaceutics and Analytical Methods of natural products.